Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors

@article{Camacho2006PhaseID,
  title={Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors},
  author={Luis H Camacho and Jon Olson and William P. Tong and Charles W. Young and David R. Spriggs and Mark G. Malkin},
  journal={Investigational New Drugs},
  year={2006},
  volume={25},
  pages={131-138}
}
Background: Phenylbutyrate (PBA), and its metabolite phenylacetate (PAA), induce growth inhibition and cellular differentiation in multiple tumor models. However, despite their potential anti-cancer properties, several pharmacodynamic aspects remain unknown. Methods: We conducted a dose escalating trial to evaluate twice-daily intravenous PBA infusions for two consecutive weeks (Monday through Friday) every month at five dose levels (60–360 mg/kg/day). Twenty-one patients with the following… CONTINUE READING
29 Extracted Citations
42 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 29 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 42 references

Clinical modulation of gene transcription Via inhibition of histone deacetylase using all-trans retinoic acid plus sodium phenylbutyrate

  • LH Camacho, S Novick, +4 authors Jr.
  • Proceedings of the Am Soc Clin Oncol,
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…